Erleada 60mg (apalutamide)

- Indication: Treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC)

- Dosage form: 60mg film-coated tablets

- Recommended dose: 240mg (four 60mg tablets) once daily

- Administration: Take with or without food, swallow tablets whole

Please consult a healthcare professional for personalized advice on Erleada treatment